Four-year follow-up on the Albany experience with intrapleural BCG in lung cancer.
One hundred sixty-nine patients were entered into randomized controlled studies of intrapleural bacille Calmette Guérin (BCG) immunotherapy after surgical resection of lung cancer. Long-term follow-up of our initial series of BCG-treated patients with Stage I disease continues to indicate that this treatment was superior to that given to control patients. The recurrence rate in the control population was high, 62% at 3 years. The recurrence rate was 33% at 3 years in the BCG-treated group. A negative preoperative tuberculin test and squamous cell histologic type were favorable prognostic factors for BCG-treated patients. The survival of patients with more advanced disease was not improved by BCG immunotherapy.
D001500:BCG Vaccine / Q000008:administration & dosage / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000601:surgery* / Q000628:therapy; D002986:Clinical Trials as Topic; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007167:Immunotherapy; D007538:Isoniazid / Q000627:therapeutic use; D008175:Lung Neoplasms / Q000601:surgery* / Q000628:therapy; D008875:Middle Aged; D010994:Pleura; D011897:Random Allocation; D013997:Time Factors
D001500:BCG Vaccine; D007538:Isoniazid